In the MFORTE trial, the survival curves for the lurbinectedin-atezolizumab arm eventually converge with the atezolizumab-only arm. This indicates the combination provides an additive benefit (delaying progression) rather than true synergy, which would have created a more durable, long-term survival advantage.
The failure of the NRG LU005 trial, giving atezolizumab with chemoradiation, suggests concurrent radiation may harm local immune cells, undermining the checkpoint inhibitor's effect. This contrasts with the successful ADRIATIC trial, where durvalumab was given after chemoradiation, highlighting the critical importance of timing.
The MFORTE trial revealed a significantly higher rate of brain-only progression in the lurbinectedin arm (27% vs 10%). This pattern suggests the drug's effective systemic control and lack of CNS penetration combine to unmask the brain as a primary sanctuary site for relapse over time.
Early data for Tarlatamab in SCLC maintenance reveals an 82% 12-month overall survival. This is an absolute 30% improvement over the experimental arm of the recent MFORTE trial, signaling a potential paradigm shift in treatment outcomes that far surpasses current immunotherapy combinations.
In the NRG LU005 trial, patients receiving BID radiation or PCI appeared to have better outcomes. The speaker warns this is likely because they were younger and healthier—a result of selection bias, not superior treatment. This serves as a critical caution against using non-randomized subgroup data for clinical decisions.